Results 201 to 210 of about 5,781 (240)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2020
e16700 Background: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is an innovative treatment for inoperable or metastasized, well/moderately differentiated, neuroendocrine tumors (NETs). Currently PRRT cannot be performed in Japan, because there is no approval and insurance cover until now.
Noritoshi Kobayashi +3 more
openaire +1 more source
e16700 Background: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is an innovative treatment for inoperable or metastasized, well/moderately differentiated, neuroendocrine tumors (NETs). Currently PRRT cannot be performed in Japan, because there is no approval and insurance cover until now.
Noritoshi Kobayashi +3 more
openaire +1 more source
Endocrine, 2014
We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC.
CAMPENNI', Alfredo +2 more
openaire +3 more sources
We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC.
CAMPENNI', Alfredo +2 more
openaire +3 more sources
European Journal of Nuclear Medicine and Molecular Imaging, 2018
Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed ...
Michela Del Prete +6 more
openaire +2 more sources
Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed ...
Michela Del Prete +6 more
openaire +2 more sources
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application
2015Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms.
Bodei, Lisa, PAGANELLI, Giovanni
openaire +1 more source
Cancer Biotherapy and Radiopharmaceuticals, 2009
Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT.From May 2005 to May 2007, 16 patients affected by neuroendocrine ...
Sierra, Maribel L. +9 more
openaire +3 more sources
Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT.From May 2005 to May 2007, 16 patients affected by neuroendocrine ...
Sierra, Maribel L. +9 more
openaire +3 more sources
Pretherapy Prediction of Nephrotoxicity After Peptide Radionuclide Receptor Therapy (PRRT)
Cancer Biotherapy and Radiopharmaceuticals, 2010Gerald L, Denardo, Daniel J, Macey
openaire +2 more sources
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Ca-A Cancer Journal for Clinicians, 2021Kyle Wang
exaly